Skip to main content

Table 5 Multivariable Cox regression analysis of all-cause death in patients with atrial fibrillation, eGFR as a category variable

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

Variable

HR represents

HR (95%CI)

P value

Total population

   

 Age

Per 1-year increment

1.018 (0.999–1.038)

0.063

 Male

Versus female

2.441 (1.475–4.040)

0.001

 Duration of AF

  

 < 0.001

  Persistent

Versus paroxysmal

0.747 (0.347–1.608)

0.455

  Permanent

Versus paroxysmal

2.187 (1.095–4.370)

0.027

 Warfarin

Yes versus no

1.329 (0.753–2.348)

0.326

 TiTR

 ≥ 66% versus < 66%

0.420 (0.122–1.443)

0.168

 eGFR

  

0.001

 60–89 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

1.304 (0.618–2.750)

0.485

  < 60 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

2.969 (1.447–6.093)

0.003

Individuals with EHRA Type 1 VHDs

   

 Age

Per 1-year increment

1.044 (0.996–1.095)

0.074

 Male

Versus female

1.912 (0.692–5.284)

0.212

 Duration of AF

  

0.367

  Persistent

Versus paroxysmal

2.006 (0.202–19.970)

0.553

  Permanent

Versus paroxysmal

3.525 (0.450–27.638)

0.231

 TiTR

 ≥ 66% versus < 66%

0.452 (0.112–1.823)

0.264

 Warfarin

Yes versus no

0.932 (0.326–2.660)

0.895

 eGFR

  

0.339

 60–89 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

1.264 (0.316–5.049)

0.740

  < 60 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

2.522 (0.587–10.843)

0.214

Individuals with EHRA Type 2 VHDs

   

 Age

Per 1-year increment

1.075 (1.004–1.151)

0.038

 Male

Versus female

2.806 (0.640–12.315)

0.171

Duration of AF

  

0.173

 Persistent

Versus paroxysmal

13.838 (0.877–218.340)

0.062

 Permanent

Versus paroxysmal

3.615 (0.583–22.423)

0.167

 CHA2DS2-VASc score

Per 1 score increment

0.619 (0.328–1.168)

0.138

 Warfarin

Yes versus no

2.447 (0.516–11.603)

0.260

eGFR

  

0.187

 60–89 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

0.517 (0.036–7.409)

0.517

 < 60 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

2.265 (0.217–23.591)

0.494

Individuals without VHDs

   

 Age

Per 1-year increment

0.993 (0.963–1.023)

0.641

 Male

Versus female

3.593 (1.684–7.667)

0.001

 Duration of AF

  

0.003

  Persistent

Versus paroxysmal

0.586 (0.234–1.465)

0.253

  Permanent

Versus paroxysmal

1.921 (0.784–4.707)

0.153

 CHA2DS2-VASc score

Per 1 score increment

1.121 (0.915–1.374)

0.271

 Warfarin

Yes versus no

1.307 (0.542–3.151)

0.550

 eGFR

  

0.007

 60–89 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

1.433 (0.546–3.763)

0.465

  < 60 ml/(min·1.73 m2)

Versus ≥ 90 ml/(min·1.73 m2)

3.660 (1.402–9.556)

0.008

  1. Models were adjusted by age, sex (male vs female), duration of AF, use of warfarin, TiTR (if available), CHADS-VASc score (if available) and eGFR. VHDs indicates valvular heart diseases
  2. CHA2DS2-VASc score was calculated by Congestive heart failure, Hypertension, Age ≥ 75 years (doubled), Diabetes mellitus, Prior Stroke or TIA (doubled), Vascular disease, Age 65 to74 years, female Sex. AF indicates atrial fibrillation
  3. TiTR time in therapeutic range, CI confidential interval, HR hazard ratio, eGFR estimated Glomerular filtration rate
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us